Hepatitis B Variants With Reduced Sensitivity To Therapeutic Compounds, Their Detection And Uses Thereof
The Present Invention Is A Diagnostic Kit And Materials For: 1) The Prediction Of The Long-Term Response Of A Chronic Hepatitis B Virus (Hbv) Carrier To Treatment With Nucleoside/Nucleotide Analogue, Or Their Combination; 2) The Detection Of Hbv Variants That Exhibit Reduced Reactivity To Antibody Detection; 3) The Detection Of Hbv Variants In The Precore/Core Region That Negatively Affect The Course Of Liver Disease; 4) The Identification Of The Hbv Genotype.
Patent Number: US20090253123A1
Application Number: US2009384132A
Inventor: Chan, Kaimin | Chan, Vivian Nap Yee | Lai, Ching Lung | Yuen, Man Fung
Priority Date: 5 Apr 2008
Priority Number: US20090253123A1
Application Date: 31 Mar 2009
Publication Date: 8 Oct 2009
IPC Current: C12Q000170 | C12Q000168
US Class: 435005 | 435006
Title: Hepatitis B variants with reduced sensitivity to therapeutic compounds, their detection and uses thereof
Usefulness: Hepatitis B variants with reduced sensitivity to therapeutic compounds, their detection and uses thereof
Summary: The methods and kits are useful for determining whether HBV extracted from a patient's biological sample exhibits reduced sensitivity to LMV, ADV, and/or to other nucleoside/nucleotide analogues, interferons, or other anti-HBV agents; determining whether HBV exhibits reduced reactivity to antibodies such as vaccine escape, immunoglobulin therapy escape or anti-HBV serological assays escape or a combination; determining the genotype of HBV; and detecting mutations and/or genotypes of HBV variants (all claimed).
生物醫學
病原
香港
